Business Context and Reporting Period
Company: Zimmer Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2007
Event: Settlement of an ongoing federal investigation into the Company's financial relationships with consulting orthopaedic surgeons.
Key Financial Metrics
Settlement Payment: $169.5 million cash payment to the U.S. government.
Expected Expense: The Company expects to record an expense of $169.5 million in the third quarter of 2007.
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Agreements
The Company entered into three definitive agreements to resolve the investigation without admitting wrongdoing:
- Civil Settlement Agreement: Resolves civil and administrative claims with the U.S. Department of Justice and the Office of Inspector General (OIG).
- Corporate Integrity Agreement: A five-year agreement with the OIG acknowledging the Company's compliance program and mandating specific compliance activities.
- Deferred Prosecution Agreement: An 18-month agreement with the U.S. Attorney's Office for the District of New Jersey. Criminal charges will not be pursued if the Company pays the settlement and complies with terms.
Oversight: The Company will be subject to oversight by a federal monitor appointed by the Department of Justice for the 18-month term of the Deferred Prosecution Agreement.
Outlook, Risks, and Contingencies
Management Commentary: The settlement resolves the specific federal investigation regarding financial relationships with surgeons. The Company disclaims any obligation to update forward-looking statements.
Risks and Uncertainties: The filing highlights several risks that could cause actual results to differ from expectations, including:
- Compliance with the Deferred Prosecution Agreement (through March 2009) and Corporate Integrity Agreement (through 2012).
- Outcome of a separate Department of Justice Antitrust Division investigation announced in June 2006.
- Product liability and intellectual property litigation losses.
- Reimbursement levels from third-party payors and general economic conditions.
Investor Verification Checklist
- Verify the impact of the $169.5 million expense on the Company's third-quarter 2007 earnings and cash position.
- Review the full text of the Settlement Agreement, Corporate Integrity Agreement, and Deferred Prosecution Agreement (Exhibits 10.1, 10.2, and 10.3) for specific compliance obligations.
- Monitor the status of the separate Department of Justice Antitrust Division investigation mentioned in the risk factors.
- Assess the potential costs and operational impact of the 18-month federal monitor oversight.